A cohort of patients with COVID-19 in a major teaching hospital in Europe

Borobia, Alberto M.; Carcas, Antonio J.; Arnalich, Francisco; Álvarez-Sala, R.; Montserrat, Jaime; Quintana, Manuel; Figueira, Juan Carlos; Santos-Olmo, Rosario María Torres; García-Rodríguez, Julio; Martín-Vega, Alberto; Buño, Antonio; Ramı́rez, Elena; Martínez-Alés, Gonzalo; Les, Nicolás García-Arenzana; Nuñez, María Concepción; Martí-de-Gracia, M.; Ramos, Francisco; Reinoso-Barbero, Francisco; Martín-Quirós, Alejandro; Núñez, Angélica Rivera; Mingorance, Jesús; Carpio, Carlos; Arribas, Daniel Prieto; Cuevas, Esther Rey; Sánchez, Concepción Prados; Ríos, Juan José; Hernán, Miguel A.; Frías, Jesús; Arribas, José Ramón

doi:10.1101/2020.04.29.20080853

Cited by 125 publications

(203 citation statements)

References 10 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…Borobia et al [23] from La Paz University Hospital, Madrid, Spain, in a sample of 2,226 adult patients (median age 61 years) admitted to hospital who either died (20.7%) or were discharged (79.3%), identified that the most common comorbidity was hypertension (41.3%), followed by other chronic cardiovascular diseases (19.3%) and diabetes (17.1%); asthma was identified in 5.2% of COVID-19 patients, with a lower prevalence rate of 3.7% in the fatal cases. COPD affected 6.9% of the population, with a prevalence of 14.1% in the fatal cases.…”

Section: Methodsmentioning

confidence: 99%

Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review

Morais‐Almeida

Pité

Aguiar

et al. 2020

Int Arch Allergy Immunol

105

View full text Add to dashboard Cite

Even though respiratory viruses are one of the most common triggers for asthma exacerbations, not all of these viruses affect patients equally. There is no strong evidence supporting that patients with asthma have a higher risk of becoming seriously ill from coronavirus disease 2019 (CO-VID-19), although recent reports from the USA and the UK suggest that asthma is much more common in children and adults with mild to severe COVID-19 than has previously been reported in Asia and in Europe. As in previous severe acute respiratory syndrome (SARS) outbreaks, patients with asthma, especially children, appear to be less susceptible to the coronavirus with a low rate of asthma exacerbations. A different expression of viral receptors and T2 inflammation can be responsible for different outcomes. Future studies focused on asthma and on other allergic disorders are needed to provide a greater understanding of the impact of underlying asthma and allergic inflammation on COVID-19 susceptibility and disease severity. However, for the moment, it is crucial that asthmatic patients maintain their controller medication, from inhaled corticosteroids to biologics, without making any dose adjustments on their own or stopping the medication. New data are emerging daily, rapidly updating our understanding of this novel coronavirus.

show abstract

Section: Methodsmentioning

confidence: 99%

Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review

Morais‐Almeida

Pité

Aguiar

et al. 2020

Int Arch Allergy Immunol

105

View full text Add to dashboard Cite

show abstract

“…Common co-morbidities (HCV [ 10 ], and chronic obstructive pulmonary disease (COPD) [ 11 ]) among PWUD are linked to adverse outcomes of COVID-19. In addition, COVID-19 mortality is associated with older age and smoking [ 12 ], both of which are common in PWUD [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

The impact of the COVID-19 pandemic on harm reduction services in Spain

Picchio

Valencia²,

Doran

et al. 2020

Harm Reduct J

View full text Add to dashboard Cite

Background Containment policies and other restrictions introduced by the Spanish government in response to the COVID-19 pandemic present challenges for marginalised populations, such as people who use drugs. Harm reduction centres are often linked to social services, mental health services, and infectious disease testing, in addition to tools and services that help to reduce the harms associated with injecting drugs. This study aimed to explore the impact of the pandemic on these services in four autonomous communities in Spain. Methods This is a cross-sectional study that employed a seven-section structured survey administered electronically to 20 centres in July 2020. Data from the most heavily affected months (March–June) in 2020 were compared to data from the same period in 2019. Averages were calculated with their ranges, rates, and absolute numbers. Results All 11 responding centres reported having had to adapt or modify their services during the Spanish state of alarm (14 March–21 June 2020). One centre reported complete closure for 2 months and four reported increases in their operating hours. The average number of service users across all centres decreased by 22% in comparison to the same period in the previous year and the average needle distribution decreased by 40% in comparison to 2019. Most centres reported a decrease in infectious disease testing rates (hepatitis B and C viruses, human immunodeficiency virus, and tuberculosis) for March, April, and May in 2020 compared to the previous year. Reported deaths as a result of overdose did not increase during the state of alarm, but 2/11 (18%) centres reported an increase in overdose deaths immediately after finalisation of the state of alarm. Conclusion Overall, Spanish harm reduction centres were able to continue operating and offering services by adjusting operating hours. The number of overall service users and needles distributed fell during the Spanish state of alarm lockdown period, suggesting that fewer clients accessed harm reduction services during this time, putting them at greater risk of reusing or sharing injecting equipment, overdosing, acquiring infectious diseases with decreased access to testing or discontinuing ongoing treatment such as methadone maintenance therapy, hepatitis C treatment, or antiretroviral therapy.

show abstract

“…The pandemic of SARS-CoV-2 infection at the beginning of 2020 has heavily hit most countries in the world, and one of the major challenges imposed by this infection has been the large numbers of patients in need for intensive care [1][2][3]. Bacterial and fungal superinfection during Intensive Care Unit (ICU) stay has been reported in other outbreaks of severe acute respiratory syndrome (SARS), but there is limited data available regarding COVID-19 patients.…”

Section: Introductionmentioning

confidence: 99%

Nosocomial infections associated to COVID-19 in the Intensive Care Unit. Clinical characteristics and outcome

Bardi

Pintado

Gómez-Rojo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Bacterial and fungal co-infection has been reported in patients with COVID-19, but there is limited experience on these infections in critically ill patients.Aim: To assess the characteristics and outcome of ICU-acquired infections in COVID-19 patients.Methods: In this retrospective single-centre, case-control study, we included 140 patients with severe COVID-19 admitted to the ICU between March and May 2020. We evaluated the epidemiological, clinical and microbiological features, and outcome of ICU-acquired infections.Results: Fifty seven patients (40.7%), developed a bacterial or fungal nosocomial infection during ICU stay. Infection occurred after a median of 9 days (IQR 5-11) of admission, and was significantly associated with the APACHE II score (p=0.02). There were 91 episodes of infection: primary (31%) and catheter-related (25%) bloodstream infections were the most frequent, followed by pneumonia (23%), tracheobronchitis (10%) and urinary tract infection (8%), that were produced by a wide spectrum of Gram positive (55%) and Gram negative bacteria (30%) as well as fungi (15%). In 60% of cases, infection was associated with septic shock, and a significant increase in SOFA score. Overall ICU mortality was 36% (51/140). Infection was significantly associated with death (OR 2.7, 95% CI 1.2-5.9, p=0.015), and a longer ICU stay (p<0.001).Conclusions: Bacterial and fungal nosocomial infection is a common complication of ICU admission in patients with COVID-19. It usually presents as a severe form of infection and it is associated with a high mortality and longer course of ICU stay.

show abstract

A cohort of patients with COVID-19 in a major teaching hospital in Europe

Cited by 125 publications

References 10 publications

Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review

Asthma and the Coronavirus Disease 2019 Pandemic: A Literature Review

The impact of the COVID-19 pandemic on harm reduction services in Spain

Nosocomial infections associated to COVID-19 in the Intensive Care Unit. Clinical characteristics and outcome

Contact Info

Product

Resources

About